247 related articles for article (PubMed ID: 33304759)
1. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.
Feng L; Chao J; Tian E; Li L; Ye P; Zhang M; Chen X; Cui Q; Sun G; Zhou T; Felix G; Qin Y; Li W; Meza ED; Klein J; Ghoda L; Hu W; Luo Y; Dang W; Hsu D; Gold J; Goldman SA; Matalon R; Shi Y
Adv Sci (Weinh); 2020 Dec; 7(23):2002155. PubMed ID: 33304759
[TBL] [Abstract][Full Text] [Related]
2. Developing Hypoimmunogenic Human iPSC-Derived Oligodendrocyte Progenitor Cells as an Off-The-Shelf Cell Therapy for Myelin Disorders.
Feng L; Chao J; Ye P; Luong Q; Sun G; Liu W; Cui Q; Flores S; Jackson N; Shayento ANH; Sun G; Liu Z; Hu W; Shi Y
Adv Sci (Weinh); 2023 Aug; 10(23):e2206910. PubMed ID: 37271923
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type
Chao J; Feng L; Ye P; Chen X; Cui Q; Sun G; Zhou T; Tian E; Li W; Hu W; Riggs AD; Matalon R; Shi Y
iScience; 2022 Jun; 25(6):104391. PubMed ID: 35637731
[TBL] [Abstract][Full Text] [Related]
4. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
5. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
6. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
7. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
8. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D
Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133
[TBL] [Abstract][Full Text] [Related]
9. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M
Exp Anim; 2024 Mar; ():. PubMed ID: 38538326
[TBL] [Abstract][Full Text] [Related]
10. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
11. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
[TBL] [Abstract][Full Text] [Related]
12. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
14. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
15. Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice.
Fröhlich D; Kalotay E; von Jonquieres G; Bongers A; Lee B; Suchowerska AK; Housley GD; Klugmann M
Front Mol Neurosci; 2022; 15():1061257. PubMed ID: 36568275
[TBL] [Abstract][Full Text] [Related]
16. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
17. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
18. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
[TBL] [Abstract][Full Text] [Related]
19. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
[TBL] [Abstract][Full Text] [Related]
20. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
